SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark discovers new drug molecule; clinical trials by 2011

31 Aug 2010 Evaluate

Glenmark Pharmaceuticals has discovered a new drug molecule, which could be used for treating pain and respiratory disorders. The new drug molecule, codenamed ‘GRC 17536’, has completed pre-clinical trials (animal tests) and will move into clinical trials (tests on humans) in the first quarter of 2011.

GRC 17536 is another potential first-in-class globally and the results shown by the molecule in animal studies is encouraging. It has proven highly efficacious in treating inflammatory and neuropathic pain in animal models, compared to gold standard drugs. Glenmark has already filed multiple patent applications for these molecules. The company’s Novel Chemical Entity (NCE) programme is targeting pain and respiratory disorders.

crackcrack

Glenmark Pharma Share Price

2190.75 27.85 (1.29%)
13-Apr-2026 15:12 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1652.00
Dr. Reddys Lab 1234.85
Cipla 1211.95
Zydus Lifesciences 923.25
Lupin 2315.85
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×